Elifor 50mg 28 long-acting tablets — Made in Germany — Free Delivery

Indications

Treatment of major depressive disorder (HCV).

Contraindications

Hypersensitivity to desvenlafaxine succinate, venlafaxine hydrochloride or any of the excipients in Elifor.

Simultaneous use of MAO inhibitors or their use within 7 days after stopping treatment with Elifor. The use of Elifor within 14 days after the abolition of MAO inhibitors.

Concomitant treatment with MAO inhibitors such as linezolid or intravenous methylene blue therapy.

Composition

active ingredient: 1 tablet of prolonged action contains desvenlafaxine succinate in an amount equivalent to 50 mg or 100 mg of desvenlafaxine

excipients: microcrystalline cellulose (Avicel PH102), microcrystalline cellulose (Avicel PH105), talc, magnesium stearate, hypromellose 2208, 100000 CR; for tablets of 100 mg Opadry II, 85F94527 (polyvinyl alcohol, macrogol, titanium dioxide (E 171), talc, FD & C Yellow # 6 / Sunset Yellow FCF Aluminum Lake (E 110), iron oxide red (E172)) for tablets 50 mg each Opadry II, 85F94487 (polyvinyl alcohol, macrogol, titanium dioxide (E 171), talc, yellow iron oxide (E172), red iron oxide (E172)).

Dosage and administration

The recommended dose of Elifor is 50 mg once daily with or without food.

Elifor should be taken at about the same time each day. Tablets should be swallowed whole with liquid, not broken, not crushed, not chewed, not dissolved.

In clinical studies, doses from 50 to 400 mg per day were effective, no additional effect was observed from the use of the preparation in doses of more than 50 mg per day, and adverse reactions and the risk of developing a withdrawal syndrome were frequent at higher doses. If the physician, based on the results of the clinical evaluation of the patient's condition, decides that an increase in the dose above 50 mg per day is appropriate for a particular patient, the maximum recommended dose should not exceed 100 mg per day.

During discontinuation of therapy, a gradual dose reduction is recommended, if possible, in order to minimize withdrawal symptoms.

Application in special groups

Patients with impaired renal function

Patients with impaired liver function

The recommended dose for patients with moderate to severe hepatic impairment is 50 mg per day. Increasing the dose above 100 mg per day is not recommended.

Supportive care

There is general agreement that acute episodes of HCV require continuous preparation  therapy for several months or longer. The efficacy of long-term use of Elifor (50-400 mg) has been established in two studies of maintenance therapy. A periodic assessment of the patient's condition should be carried out to determine the need to continue therapy.